Restore

Access to Advanced Wound Care at the Bedside Expands Across US

Retrieved on: 
Tuesday, April 2, 2024
Communication, Patient, Travel, RFH, Restore, Multimedia, Physician, Nursing

ATLANTA, April 2, 2024 /PRNewswire/ -- Restore First Health (RFH) expands access to advanced wound care in Florida, Colorado and Kansas, creating opportunities for more patients across the country to heal from chronic wounds. Formerly known as Restore Wound Care, based in Thornton, Colorado and Restore Medical Group Midwest, based in Wichita, Kansas, will now become part of the Restore First Health mobile wound program headquartered in Atlanta, Ga.

Key Points: 
  • ATLANTA, April 2, 2024 /PRNewswire/ -- Restore First Health (RFH) expands access to advanced wound care in Florida, Colorado and Kansas, creating opportunities for more patients across the country to heal from chronic wounds.
  • A leader in bedside care management of chronic wounds, clinicians' expertise in wound care allow for high-level care coordination to see a patient's holistic needs to management of chronic wounds.
  • "Our goal is to build our chronic wound program while supporting innovation and collaboration with partners in wound care along the way."
  • Focused on innovative approaches to advanced wound care at the bedside, the program is now caring for patients in Georgia, New Jersey, Pennsylvania, Colorado, Kansas and Florida.

Pet Honesty® Introduces Groundbreaking Restore + Soothe Line, Elevating Pet Skincare with MicroSilver BG™ Innovation

Retrieved on: 
Wednesday, February 21, 2024
Veterinary, Other Retail, Pets, Specialty, Health, Cosmetics, Consumer, Retail, Online Retail, Restore, Bacteria, Oil, Dog, Soothe, Paraben, Skin, Veterinarian, Skin care, Research and development, Sulfate, Vaccine

Pet Honesty ®, a leading vet-recommended and natural pet health supplements brand, proudly unveils its revolutionary Restore + Soothe line, a sophisticated range of skincare products featuring the powerful, all-natural MicroSilver BG™.

Key Points: 
  • Pet Honesty ®, a leading vet-recommended and natural pet health supplements brand, proudly unveils its revolutionary Restore + Soothe line, a sophisticated range of skincare products featuring the powerful, all-natural MicroSilver BG™.
  • At the core of the Restore + Soothe line is MicroSilver BG™, a clinically studied ingredient crafted from pure, elemental silver.
  • Greg Reinhart, Ph.D, Vice President of Research & Development at Pet Honesty, expressed enthusiasm for MicroSilver BG™, stating, “MicroSilver BG™ is a game-changer in pet skincare.
  • The Restore + Soothe Spray ($14.99) offers fast relief in a natural formulation, and the Restore + Soothe Ear Cleaner ($19.99) provides quick relief for ear issues.

Napp announces authorisation of REZZAYO® (rezafungin) in Great Britain by the UK Medicines and Healthcare Products Regulatory Agency for the treatment of invasive candidiasis in adults1

Retrieved on: 
Friday, February 2, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Multimedia, Hypokalemia, Tremor, Mortality, Mycology, Immunodeficiency, Hospice and palliative medicine, Nausea, MHRA, Immune system, UV, Candidiasis, Anemia, Caspofungin, Disease, Wheeze, Patient, Safety, DRC, Abdominal pain, Flushing, Diagnosis, Erythema, Hyponatremia, Rash, Sensation, Royal College of Pathologists, Radiation, Hypotension, Constipation, Risk, Vomiting, Restore, Medication, Phototoxicity, Infection, Medicine, Common, ODD, Diarrhea, Mitt, Pharmaceutical industry

Napp Pharmaceuticals Limited, a member of the international network of Mundipharma independent associated companies, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised rezafungin for the treatment of invasive candidiasis in adults in Great Britain (GB).1,2

Key Points: 
  • Napp Pharmaceuticals Limited, a member of the international network of Mundipharma independent associated companies, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised rezafungin for the treatment of invasive candidiasis in adults in Great Britain (GB).1,2
    This press release features multimedia.
  • Common adverse reactions include anaemia, hypomagnesaemia, hypophosphataemia, hypotension, wheezing, vomiting, nausea, abdominal pain, constipation, erythema, and rash.
  • Increased blood alkaline phosphatase, hepatic enzymes, alanine aminotransferase, aspartate aminotransferase and blood bilirubin were also common.
  • Transient infusion-related reactions have occurred with rezafungin, characterised by flushing, sensation of warmth, nausea, and chest tightness.2
    Rezafungin may cause increased risk of phototoxicity.

Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial & Phase 2 STRIVE Trial of REZZAYO® (rezafungin for injection) for the Treatment of Candidemia & Invasive Candidiasis in The Lancet ID

Retrieved on: 
Tuesday, December 5, 2023
Other Health, Research, Managed Care, Pharmaceutical, Hospitals, Clinical Trials, Science, Surgery, Biotechnology, FDA, Other Science, Health, CDTX, Lancet, NDA, Priority review, Disease, Safety, Food, Melinta Therapeutics, European Medicines Agency, Therapy, NTAP, Injection, Randomized controlled trial, QIDP, The Lancet, MAA, Mortality, Restore, EMA, Patient, Caspofungin, CHMP, Marketing, Advanced Therapy Medicinal Product, New Drug Application, CMS, MPH, Medicare, Hospital, Pharmaceutical industry, MD, Fungemia

These findings are of clinical importance given the ongoing morbidity and mortality caused by candidemia and invasive candidiasis.

Key Points: 
  • These findings are of clinical importance given the ongoing morbidity and mortality caused by candidemia and invasive candidiasis.
  • On March 22, 2023, the FDA approved REZZAYO for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.
  • REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over fifteen years.
  • In October, the EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for rezafungin (rezafungin acetate) for the treatment of invasive candidiasis in adults.

Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)

Retrieved on: 
Friday, October 13, 2023
European, Infection, Restore, Committee for Medicinal Products for Human Use, CHMP, Fungal infection, European Medicines Agency, DFC, CDTX, Mortality, European Commission, Tavarua, Safety, Disease, EMA, Medical Mycology, FDA, Therapy, Phase, EC, Mycology, Committee, Immune system, SAN, News, Candidiasis, Civil service commission, Caspofungin, Patient, Medical device, Pharmaceutical industry, Vaccine, Mundipharma

A new treatment option for these serious infections is a much-needed addition.”

Key Points: 
  • A new treatment option for these serious infections is a much-needed addition.”
    “We would like to thank the CHMP for their careful consideration of the use of rezafungin.
  • This positive opinion represents an important step on the journey towards approval and brings us closer to providing clinicians with an alternative treatment option for invasive Candida infections, giving hope to patients battling this infection and their families,” said Brian Sheehan, Ph.D., Chief Scientific Officer at Mundipharma.
  • The CHMP’s positive opinion on rezafungin for the treatment of serious fungal infections, such as invasive candidiasis in adults, will be referred to the European Commission (EC), which will deliver a final decision in approximately two months.
  • Cidara Therapeutics has partnered with Mundipharma, which has commercial rights to rezafungin outside the U.S. and Japan.

Mundipharma and Cidara Therapeutics receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults1

Retrieved on: 
Friday, October 13, 2023
Health, Infectious Diseases, Other Science, Clinical Trials, Science, Pharmaceutical, Biotechnology, European, Multimedia, Infection, Restore, Committee for Medicinal Products for Human Use, CHMP, Fungal infection, European Medicines Agency, CDTX, Mortality, European Commission, Safety, Disease, EMA, Medical Mycology, FDA, Therapy, Phase, EC, Mycology, Committee, News, Candidiasis, Civil service commission, Caspofungin, Patient, Vaccine, Pharmaceutical industry, Mundipharma

Mundipharma and Cidara Therapeutics (Nasdaq: CDTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for rezafungin (rezafungin acetate) for the treatment of invasive candidiasis in adults.1

Key Points: 
  • Mundipharma and Cidara Therapeutics (Nasdaq: CDTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for rezafungin (rezafungin acetate) for the treatment of invasive candidiasis in adults.1
    This press release features multimedia.
  • A new treatment option for these serious infections is a much-needed addition.”
    “We would like to thank the CHMP for their careful consideration of the use of rezafungin.
  • The CHMP’s positive opinion on rezafungin for the treatment of serious fungal infections, such as invasive candidiasisin adults, will be referred to the European Commission (EC), which will deliver a final decision in approximately two months.
  • Cidara Therapeutics has partnered with Mundipharma, which has commercial rights to rezafungin outside the U.S. and Japan.

ServiceMaster Recovery Management® Opens New Commercial Operations Center in Kansas

Retrieved on: 
Monday, October 9, 2023
Naval Landing Force Equipment Depot, Commercial Operating System, ServiceMaster, Communication, SRM, Strategic planning, Growth, Restore, AR, Joint Maritime Training Center, AP, Warehouse

ATLANTA, Oct. 9, 2023 /PRNewswire/ -- ServiceMaster Recovery Management (SRM), the large-loss commercial restoration division of ServiceMaster Restore ®,  is thrilled to announce the grand opening of its new 55,000 square feet Commercial Operations Center.

Key Points: 
  • ATLANTA, Oct. 9, 2023 /PRNewswire/ -- ServiceMaster Recovery Management (SRM), the large-loss commercial restoration division of ServiceMaster Restore ®,  is thrilled to announce the grand opening of its new 55,000 square feet Commercial Operations Center.
  • Key features of the new Commercial Operations Center include:
    Headquarters of strategic planning and business development efforts for our SRM Commercial Team.
  • "With this new Commercial Operations Center, we take a giant leap forward, expanding the horizons of ServiceMaster Restore and ServiceMaster Recovery Management networks, ushering in an era of accelerated growth."
  • - John Tovar, President, ServiceMaster Restore
    The grand opening of the Commercial Operations Center is a testament to ServiceMaster Recovery Management and ServiceMaster Restore's commitment to innovation, customer satisfaction, franchise support and network growth.

Apple unveils its first carbon neutral products

Retrieved on: 
Tuesday, September 12, 2023
Environmental Health, Other Manufacturing, Consumer Electronics, Technology, Packaging, Sustainability, Recycling, Logistics, Supply Chain Management, Specialty, Manufacturing, Environmental, Social and Governance (ESG), Climate Change, Retail, Environment, Green Technology, Alternative Energy, Transport, Energy, Professional Services, Wearables, Mobile Technology, Environmental Issues, Carbon, Climate, Apple Watch, Aluminium, Adhesive, Electricity, Forest, Investment, SE, MagSafe, Wetland, IPhone, IPad, Atmosphere, Apple Inc., Home Office hostile environment policy, Forest Stewardship Council, IOS, Certification, Name, Cobalt, Hi-5 (series 9), Mac, Double, Carbon footprint, Climate change, Multimedia, Restore, Home, B-24 Liberator Memorial Restoration Fund, United Nations, Metal, Alpine Loop, Wind, Intergovernmental Panel on Climate Change, Community, Weather, Farm, Renewable energy, Mobile phone, Agriculture, Policy, Apple

Apple® today announced its first-ever carbon neutral products in the all-new Apple Watch® lineup.

Key Points: 
  • Apple® today announced its first-ever carbon neutral products in the all-new Apple Watch® lineup.
  • In 2020, Apple achieved carbon neutrality for its global corporate operations and announced Apple 2030: a bold strategy to be carbon neutral across its entire value chain by 2030.
  • All manufacturing for the carbon neutral Apple Watch models is powered by 100 percent clean electricity through investments and sourcing by Apple and its suppliers.
  • Apple, the Apple logo, Apple Watch, iPhone, Apple Watch Ultra, MagSafe, iPad, and Mac are trademarks of Apple.

Service Environments of Texas and Beartown Restore Group Unite for Growth

Retrieved on: 
Monday, August 14, 2023
European Wax Center, BRG, SET, Growth, Hollibaugh, ServiceMaster, Acquisition, Massage, Restore

ATLANTA, Aug. 14, 2023 /PRNewswire/ -- ServiceMaster Restore® is excited to announce that Beartown Restore Group (BRG), a leading franchise brand builder, has acquired Service Environments of Texas (SET), a ServiceMaster Restore franchise owned by Brad Hollibaugh.

Key Points: 
  • ATLANTA, Aug. 14, 2023 /PRNewswire/ -- ServiceMaster Restore® is excited to announce that Beartown Restore Group (BRG), a leading franchise brand builder, has acquired Service Environments of Texas (SET), a ServiceMaster Restore franchise owned by Brad Hollibaugh.
  • With a strong track record of building multi-site services businesses, BRG aims to continue building the ServiceMaster business in Houston and beyond.
  • The addition of Restore marks the BRG team's third franchise investment in a growing portfolio which includes European Wax Center and Massage Envy, and it is a testament to its confidence in the Restore brand.
  • We look forward to watching the continued growth and success of Service Environments of Texas under BRG's leadership.

Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™

Retrieved on: 
Monday, April 24, 2023
Restore, Therapy, Biotechnology, Food, H3N2, Janssen, CD73, CDTX, Fungemia, DFC, Patient, SAN, Fungal infection, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Safety, Pharmaceutical industry, Melinta Therapeutics

SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today announced receipt of a $20 million milestone payment from Melinta Therapeutics following the U.S. Food and Drug Administration (FDA) approval of REZZAYO™ (rezafungin for injection), a novel, once-weekly echinocandin antifungal approved for the treatment of candidemia and invasive candidiasis.

Key Points: 
  • The approval was based on positive data from Cidara’s global ReSTORE Phase 3 trial and supported by the STRIVE Phase 2 clinical trial and extensive non-clinical development program.
  • Last year, Melinta acquired exclusive rights to commercialize REZZAYO in the U.S. from Cidara.
  • “With the $20 million milestone payment from Melinta, Cidara remains eligible to receive additional non-dilutive capital of up to approximately $47 million in development and regulatory milestones from our existing partnerships based on successful completion of activities planned for the next year.
  • Cidara is additionally advancing its first oncology DFC candidate, CD421, a first-in-class inhibitor of CD73, with an IND anticipated in 2024.